Market Analysis of Tetracycline and Chloramphenicol in Week 16
Doxycycline hydrochloride fell, and the market price was around 450, down 15% from the previous month. The price in the same period in December 2021 was 645, and the price continued to dive from January 2022. The recent price drop of doxycycline hydrochloride, which has experienced wind and rain, also caught us by surprise. We will continue to pay attention to it later.
Oxytetracycline and Oxytetracycline Hydrochloride are hovering at a low level, and there is a lot of room for bargaining. The price of Oxytetracycline has remained in the range of 83-86 in the past three years, and the price of Oxytetracycline Hydrochloride is low, and the quotation is 102-105
Florfenicol, rebounded slightly, loose on the outside and tight on the inside, the market price is 425-440, the current price has bottomed out, the market purchase psychological expectations are high, the upstream terminal delivery is tight, the price in the same period last year was around 580.
Chlortetracycline hydrochloride, running at a low level, the market price is around 210; manufacturers of chlortetracycline hydrochloride: Fujian Fukang, Pucheng Zhengda, Jinhe Biotechnology
Looking for chemical products? Let suppliers reach out to you!
2026-06-19
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Market Analysis of Domestic Veterinary Drug Raw Materials in the 34th Week of 2022
-
Analysis of The Domestic Tetracycline And Chloramphenicol Market in The 17th Week of 2022
-
Analysis of The Domestic Tetracycline And Chloramphenicol Market in The 17th Week of 2022
-
Market Analysis of Tetracycline and Chloramphenicol Raw Materials
-
Market Analysis of Tetracycline and Chloramphenicol Raw Materials
-
Market Analysis of Tetracycline And Chloramphenicol
-
Market Analysis of Tetracycline And Chloramphenicol
-
Betting on Next-Generation Metabolic Therapies: Pfizer’s Big Wager on Metsera and Its Strategic Reshaping in China
-
The GLP-1 Sweet Shot in India’s Diabetic Gut
-
Merck Nears Acquisition of Cidara to Strengthen Flu Prevention Arsenal
Recommend Reading
-
Small Pharma Firms Under Threat as Regulator Tightens Quality Norms
-
Sun Pharma’s Utreglutide Shows Promising Weight Loss and Liver Fat Reduction
-
Biocon Weighs Merger of Biocon Biologics to Unlock Value
-
The $6 Billion Gold Rush: Generic Semaglutide Set to Reshape Global Pharma After Patent Cliff
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
This Week, the Transaction Focus of China's Propylene Oxide Market Rises (11.10-11.14)
-
This Week's Epichlorohydrin Market Transaction Focus Shifted Upward and Stabilized (11.10-11.14)
-
BASF Partners with Andritz for Carbon Capture Project in Aarhus
-
LANXESS Expands Rubber Additives Production at Qingdao Plant
-
BASF Plans IPO for Agricultural Solutions Business